Tenderwize
Back to tender search

Non-exclusive pharmaceutical rebate agreement for Ipratropiumbromid

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2027 · 374 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No minimum quantities guaranteed; actual demand depends on many factors and may be very low.

Buyer may terminate the Open-House procedure early if exclusive rebate agreements are signed, ending all existing agree...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Non-exclusive rebate agreements for pharmaceutical product Ipratropiumbromid (excluding dosage aerosol)
  • Supply of medicines under rebate contract with AOK PLUS
Show full summary

Non-exclusive pharmaceutical rebate agreement for Ipratropiumbromid (ATC R03BB01) via an Open-House model. The buyer is AOK PLUS. No guaranteed volumes, no exclusivity, and the contract ends 30 September 2027. The notice is a transparency publication, not a formal procurement. Estimated value is not disclosed. Participation requires access to confidential documents via DTVP.

Risks

No minimum quantities guaranteed; actual demand depends on many factors and may be very low.

Buyer may terminate the Open-House procedure early if exclusive rebate agreements are signed, ending all existing agree...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur under §4 Abs.18 AMG regarding the offered medicines
  • Must comply with EU sanctions against Russia (EU Reg. 833/2014)

Eligibility

  • Must submit exclusion grounds declaration and Russia sanctions declaration

Requirements may be incomplete.

Award Criteria

Lot 1

Not applicable (Open-House model)

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical rebate agreement for Ipratropiumbromid

Non-exclusive rebate agreements for Ipratropiumbromid (excluding dosage aerosol) under §130a SGB V. Open-House model with rolling admission until 30 Sept 2027.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Sep 2026 - Sep 2027

Category

Pharmaceutical products

Award Criteria

Not applicable (Open-House model)

Deadline

Deadline Sep 30, 2027

Procurement Details

Publication date
09 Jul 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
478099-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Omalizumab (ATC-Code nach WHO: R03DX05)

Sep 30